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Abstract  Although  highly  active  antiretroviral  therapy  (HAART)  has  improved  survival  rates  of
HIV patients,  HIV-associated  neurocognitive  disorders  (HAND)  still  exist  in  a  highly  prevalent
group of  persons  with  this  disease.  In  this  study  we  seek  to  evaluate  the  inﬂuence  of  drug  use
in the  neuropsychological  performance  of  seropositive  drug  users.  We  carried  out  an  exten-
sive neuropsychological  evaluation  and  compared  the  performance  of  seropositive  drug  users
(n =  90)  with  that  of  a  control  group  of  seronegative  drug  users  (n  =  48).  The  results  reveal  that
methadone  maintenance  programmes  can  make  the  seropositive  subject  neuropsychologically
vulnerable.  Likewise,  we  found  that  giving  up  drugs  have  a  protective  effect  in  the  presence
of neuropsychological  alterations  associated  with  HIV.  These  ﬁndings  lead  us  to  suggest  that
seropositivity  is  not  sufﬁcient  to  explain  the  neuropsychological  alterations  of  seropositive  drug
users, noting  that  these  alterations  are  multifactorial.
© 2016  Fundacio´n  Universitaria  Konrad  Lorenz.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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Función  neuropsicológica  en  el  tratamiento  de  mantenimiento  con  metadona  en
pacientes  con  VIH
Resumen  Aunque  la  terapia  antirretroviral  de  gran  actividad  (TARGA)  ha  mejorado  los  índices
de supervivencia  de  los  pacientes  infectados  por  el  VIH,  los  trastornos  neurocognitivos  aso-
ciados con  el  VIH  (TNAV)  todavía  existen  en  un  grupo  de  personas  altamente  prevalente  a
esta enfermedad.  En  este  estudio  buscamos  evaluar  la  inﬂuencia  del  consumo  de  drogas  en
el rendimiento  neuropsicológico  de  los  usuarios  de  drogas  seropositivos.  Llevamos  a  cabo  una
amplia evaluación  neuropsicológica,  y  el  rendimiento  de  los  usuarios  de  drogas  seropositivos
(n =  90)  se  comparó  con  la  de  un  grupo  control  de  usuarios  de  drogas  seronegativos  (n  =  48).
Los resultados  demuestran  que  los  programas  de  tratamiento  de  mantenimiento  con  metadona
pueden convertir  en  vulnerable  a  nivel  neuropsicológico  al  individuo  seropositivo.  Asimismo,
descubrimos  que  abandonar  las  drogas  provoca  un  efecto  protector  frente  a  la  existencia  de
alteraciones  neuropsicológicas  asociadas  con  el  VIH.  Estos  resultados  nos  llevan  a  sugerir  que
la seropositividad  no  basta  para  explicar  las  alteraciones  neuropsicológicas  de  los  usuarios  de
drogas seropositivos,  ya  que  estas  alteraciones  al  parecer  son  multifactoriales.
© 2016  Fundacio´n  Universitaria  Konrad  Lorenz.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un




































































sThe  human  immunodeﬁciency  virus  (HIV)  infection  is
ssociated  with  a  wide  range  of  neuropsychological  deﬁcits:
sychomotor  functioning,  information  processing  speed,
ttention,  executive  functioning,  information  processing
peed,  attention,  executive  functioning  and  working  mem-
ry  (Al-Khindi,  Zakzanis,  &  Van  Gorp,  2011;  Blackstone
t  al.,  2012;  Cysique,  Marruf,  &  Brew,  2006;  Heaton  et  al.,
011;Vázquez-Justo,  Pin˜ón-Blanco,  Vergara-Moragues,
uillén-Gestoso,  &  Pérez-García,  2014).  The  nature  of
hese  deﬁcits  is  compatible  with  an  affection  of  the
rontal-subcortical  brain  disturbances,  including  cerebral
etabolite  abnormalities  (Cohen  et  al.,  2010;  Paul  et  al.,
008)  and  white  matter  damage  (Coughlin  et  al.,  2014;
ellows,  Byrd,  &  Morgello,  2014)  and  their  prevalence
aries  considerably  (Cohen  et  al.,  2015;  Heaton  et  al.,
010;  Woods,  Moore,  Weber,  &  Grant,  2009).
The  variability  of  the  data  on  the  prevalence  of
hese  alterations  leads  us  to  consider,  as  Anand,  Springer,
openhaver,  and  Altice  (2010)  put  forward,  that  these  may
e  modulated  by  the  coexistence  of  factors  other  than  HIV.
o  deﬁnitive  risk  factors  are  yet  available  to  indicate  the
evelopment  of  these  neuropsychological  alterations  and,
earing  in  mind  that  the  presence  of  cognitive  disturbances
s  a  risk  factor  of  early  death  in  all  stages  of  the  infec-
ion  (Lescure  et  al.,  2011;  Sevigny  et  al.,  2007),  there  is
 pressing  need  to  determine  those  factors,  either  related
r  foreign  to  HIV,  which  help  to  explain  the  intra-group  dif-
erences  that  exist  and  which  may  also  be  associated  with
he  development  and  progression  of  the  dysfunction  (Anand
t  al.,  2010;  Byrd  et  al.,  2011;  Mun˜oz-Moreno  et  al.,  2008).
he  identiﬁcation  of  these  risk  factors  will  help  us  to  out-
ine  the  characteristics  of  the  seropositive  subjects  who  are
europsychologically  more  vulnerable.
Research  dealing  with  this  sphere  of  work  has  mainly
tudied  the  inﬂuence  of  variables  related  to  the  infec-
ion,  such  as  the  stage  of  infection  (Selnes  et  al.,  1997;
pudich  &  Ances,  2015),  the  level  of  immunosuppression
n
&
MFarinpour  et  al.,  2000;  Grassi,  Perin,  Borlla,  &  Mangoni,
999),  the  combined  effects  of  HIV  infection  and  APOE
4  may  lead  to  greater  cognitive  deﬁcits,  especially  in
hose  with  greater  neuroinﬂammation  (Chang,  Connaghan,
ei,  &  Li,  2014)  and  the  viral  load  (Ellis  et  al.,  1997;
un˜oz-Moreno  et  al.,  2008;  Stankoff  et  al.,  1999).  How-
ver,  they  have  also  dealt  with  determining  the  inﬂuence
f  other  variables  such  as  depressed  mood  (Fellows  et  al.,
014;  Vázquez-Justo,  Rodríguez-Álvarez,  &  Carro-Ramos,
003;  Vázquez-Justo,  Rodríguez  Álvarez,  &  Ferraces  Otero,
003),  history  of  neurological  pathology  (Hestad,  Updike,
elnes,  &  Royal  III,  1995)  and  of  psychiatric  pathology
Baldeweg  et  al.,  1997);  variables  related  to  drug  use
García-Torres,  Vergara-Moragues,  Pin˜ón-Blanco,  &  Pérez-
arcía,  2015;  Rodríguez,  2000;  Vázquez-Justo,  Rodríguez
lvarez,  &  Rodríguez  Salgado,  2000; Vergara-Moragues,
ergara  de  Campos,  &  Girón-González,  2008),  high  psychoso-
ial  stress  and  lower  socioeconomic  status  (Rubin  et  al.,
015)  and  educational  level  (Satz  et  al.,  1993).  The  ﬁndings
f  these  studies  reveal  that  the  neuropsychological  perfor-
ance  of  seropositive  subjects  may  vary  according  to  their
ituation  with  respect  to  each  of  these  variables,  although
he  results  are  not  consistent.
We  know  that  HIV  infection  in  drug  users  is  associ-
ted  with  neuropsychological  alterations  that  cannot  be
ttributed  to  the  history  of  drug  abuse  (Vázquez-Justo  et  al.,
003a,  2003b;  Vergara-Moragues,  Vergara  de  Campos,  &
irón-González,  2010).  When  evaluating  the  neuropsychol-
gical  performance  of  seropositive  drug  users,  a  variable
hat  may  affect  their  performance  is  their  current  situa-
ion  with  respect  to  drug  consumption,  i.e.  whether  they
ontinue  to  use  drugs  or  whether  they  are  abstaining  at
he  time  of  evaluation.  In  this  sense,  the  current  con-
umption  of  drugs  is  related  to  a  poorer  performance  in
europsychological  tasks  than  abstinence  (Ardila,  Rosselli,
 Strumwasser,  1991;  Grassi  et  al.,  1995).  The  Methadone

























tNeuropsychological  functioning  in  methadone  maintenance  
framework  for  evaluating  the  neuropsychological  conse-
quences  of  the  active  consumption  of  opiates.  For  example,
chronic  crack  cocaine  use  seems  to  disrupt  general  cogni-
tive  functioning  (MMSE),  verbal  memory,  and  attentional
resources,  but  ﬁndings  suggest  that  some  of  these  effects
could  be  reversed  by  abstinence  (De  Oliveira  et  al.,  2009).
In  addition,  Vázquez-Justo  et  al.  (2000)  evaluated  the
cognitive  functioning  of  drug  users  in  MMP  and  noted  a  signif-
icantly  poorer  performance  in  these  subjects  as  compared  to
those  in  abstinence.  Likewise,  Rodríguez  (2000)  pointed  out
that  the  rate  of  neuropsychological  affection  of  seropositive
subjects  in  MMP  is  double  that  of  abstaining  seropositive  sub-
jects,  observing  greater  difﬁculty  in  attention,  coordination
and  visual-motor  speed,  memory,  conceptualisation  and  ver-
bal  ﬂuency  in  the  seropositive  subjects  in  MMP  than  in  those
abstaining.
The  aim  of  this  study  is  not  only  to  contribute  to  clarifying
the  effect  of  some  factors  in  the  neuropsychological  per-
formance  of  Spanish  seropositive  subjects  but  also  to  make
progress  in  this  line  of  research  by  providing  evidence  of
the  multifactorial  nature  of  neuropsychological  deteriora-
tion  associated  with  HIV  infection.
Method
In  order  to  carry  out  this  research,  a  sample  comprising
138  male  volunteers  was  used.  All  subjects  provided  writ-
ten  informed  consent.  These  subjects  were  distributed  in
two  groups:  one  group  of  drug  users  with  HIV  infection
(n  =  90),  referred  to  as  seropositive  (HIV+),  of  this  group
of  48  subjects  were  on  the  drug-free  treatment  programme
and  42  were  on  methadone  maintenance  programme.  A  sec-
ond  group  of  controls  (HIV−), formed  by  HIV  seronegative
drug  users  (n  =  48),  of  this  group  of  27  subjects  were  on  the
drug-free  treatment  programme  and  21  were  on  methadone
maintenance  programme.  The  drug  dependent  subjects
were  recruited  in  the  HIV  services  at  Hospitals  and  at  units
for  the  care  of  drug  users  in  Galicia  (Spain).  To  be  included
in  the  study  the  intravenous  drug  users  should  be  diagnosed
as  opiate-dependent  according  to  DSM-IV  criteria.  Before
starting  on  heroin,  all  had  taken  cannabis,  amphetamines,
cocaine,  or  barbiturics,  either  simultaneously  or  consecu-
tively,  without  becoming  dependents  on  any  of  these  other
drugs,  and  primary  drug  of  choice  was  cannabis  or  alcohol
for  all  the  drug  user  subjects.
Diagnosis  of  seropositivity  and  the  classiﬁcation  of  the
subjects  regarding  phase  of  infection  was  carried  out
according  to  standard  procedures  (Centers  for  Disease
Control  [CDC],  1992),  and  was  based  on  the  medical  report
from  the  hospitals  where  the  subjects  were  recruited.
Those  subjects  who  presented,  or  had  presented,  neu-
rological  or  medical  pathologies  that  could  affect  the  CNS,
including  HIV-associated  dementia,  psychiatric  disturbances
(psychotic  symptoms),  history  of  craneo-encephalic  trauma
requiring  hospitalization  owing  to  neurological  compli-
cation,  and  antisocial  personality  disorder  according  to
DSM-IV  criteria  (American  Psychiatric  Association,  2002)
were  excluded  from  the  study.  Finally,  taking  as  a  basis  the
report  from  the  units  for  the  care  of  drug  addicts,  those
dependent  on  drugs  who  were  currently  consuming  psy-
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ethadone  were  excluded.  In  the  other  hand,  three  months
rug-free  was  required  to  be  considered  in  abstinence.
Examination  of  each  subject  consisted  of  a  semi-
tructured  interview  on  socio-demographic,  clinical  and
oxicological  aspects  and  a  neuropsychological  evaluation
ith  a  battery  of  tests  designed  for  this  study,  chosen  for
heir  validity  and  for  having  been  shown  to  be  sensitive  to
europsychological  deterioration  in  HIV-infected  patients  in
ther  studies.  The  neuropsychological  domains  and  tests  and
omprising  the  battery  are  as  follows:
.  Attention
Visual  Search  and  Attention  Test  (VSAT)  (Trenerry,
Crosson,  Beboe,  &  Leber,  1990).
.  Visual-motor  integration:
Block  Design  and  Object  Assembly  subtests  of  the
Wechsler  Adult  Intelligence  Scale  --  WAIS  --  (Wechsler,
1999).
. Motor  coordination:
Purdue  Pegboard  Test  (Tifﬁn,  1948).
Finger  Tapper  Test  (Reitan,  1979).
.  Language:
Comprehension  subtest  of  the  Wechsler  Adult  Intelli-
gence  Scale  --  WAIS  --  (Wechsler,  1999).
Verbal  Fluency  Test  (Cuadrado,  Esteba-Castillo,  Böhm,
Cejudo-Bolívar,  &  Pen˜a-Casanova,  2002).
Boston  Naming  Test  (Kaplan,  Goodglass,  &  Weintraub,
2001).
. Memory:
Rey  Auditory  Verbal  Learning  Test  --  AVLT  --  (Rey,  1964).
Rey  Osterrieth  Complex  Figure  --  ROCF  --  (Rey,  1987).
Benton  Visual  Retention  Test  --  BVRT  --:  Form  C,  Admin-
istration  A  (Benton,  1981).
.  Executive  Functions:
Similarities,  Digit  Span,  Digit  Symbol  subtests  of  the
Wechsler  Adult  Intelligence  Scale  --WAIS  --  (Wechsler,
1999).
Trail  Making  Test  --  TMT  --  (Tombaugh,  2004)
Stroop  Test  (Golden,  1994).
Wisconsin  Card  Sorting  Test  --  WCST  --  (Heaton,
Chelune,  Talley,  Kay,  &  Curtiss,  2001).
.  Cognitive  reserve:
Vocabulary  subtest  of  the  Wechsler  Adult  Intelligence
Scale  (WAIS)  (Wechsler,  1999).
.  Handeness:
Edinburgh  Handedness  Inventory  (Oldﬁeld,  1971).
esults
earing  in  mind  the  objectives  posed,  and  in  order  to
espond  to  them,  diverse  data  analyses  were  carried  out
sing  the  SPSS  statistical  packet  for  Windows.
haracteristics  of  the  Sample
irst,  an  analysis  of  variance  (ANOVA),  chi  squared  or  Student
 test  was  performed  when  needed  in  order  to  determine
hether  there  were  differences  between  the  seropositive
nd  seronegative  groups  in  the  different  socio-demographic
nd  clinical  variables.  Statistically  signiﬁcant  differences







Table  1  Group  comparisons  on  demographic  and  clinical  variables.



















(MMP)  n  =  21
Age  (years)  33  (4.8)  34  (5.3)  26  (3.8)  32  (4.1)  F  =  18.7  <.05  FTP/HIV+>FTP/HIV;
MMP/HIV+>FTP/HIV−;
FTP/HIV−<MMP/HIV−
Education (years)  10  (3.4)  10  (2.9)  10.5  (2.7)  10  (2.3)  F  =  0.166  >.05  --
Occupational attainment 2 =  15.20 .005* --
Unemployed 24  (50)  36  (85.7)  13  (48.1)  13  (61.9)
Employed 24  (50)  6  (14.3)  14  (51.9)  8  (38.1)
Economic level 2 =  1.339 .720 --
Low 15  (32.6)  18  (43.9)  10  (37)  7  (33.3)
Middle 31  (67.4)  23  (56.1)  17  (63)  14  (66.7)
Manual dominance 2 =  2.997 .392 --
Right 44  (93.6)  35  (89.7)  27  (100)  19  (90.5)
Left 3  (6.4)  4  (10.3)  --  2  (9.5)
Addiction time
(years)
8.7  (3.6)  10.7  (4.7)  6.1  (3.3)  10.9  (4.1)  F  =  8.603  <.05  MMP/HIV+>FTP/HIV−;
FTP/HIV−<MMP/HIV−
Age at  onset  drug  use  16  (2.7)  16  (2.7)  15  (3.3)  16  (3.9)  F  =  0.405  >.05  --
Months of  abstinence  64.04  (41.22)  --  11.69  (8.89)  --  t  =  6.496  .000* --
Months in  Methadone
Maintenance
Programme
--  30.81  (34.6)  --  23.38  (26.8)  t  =  939  .392  --
CD4 count  358  (318.6)  298  (315.6)  --  --  t  =  851  .397  --
Plasma viral  loads 2 =  0.254 .614 --
Detectable 18  (52.9)  12  (60)  --  --
Undetectable  16  (47.1)  8  (40)  --  --
Antirretroviral  therapy 2 =  0.068 .795 --
Receiving 27  (60)  22  (62.9)  --  --
No Receiving  18  (40)  13  (37.1)  --  --
Numbers express means and (standard deviations) for quantitative variables and percentages for qualitative variables.
















Table  2  Group  comparisons  on  neuropsychological  measures  (Mean  and  SD)  inﬂuence  of  the  situation  with  respect  to  drug  use.
Neuropsychological
test





















n  =  21
Neuropsychological  domains
Attention










Verbal ﬂuency 29.69  (9.03) 26.93  (11.04) 34.00  (7.17)  33.71  (9.67)  F  =  4.11  <.05  MMP/HIV+<FTP/HIV−;
Boston naming 53.38  (4.97) 52.28  (5.43) 54.44  (3.00)  53.76  (2.39)  F  =  1.35  >.05  --
Memory
AVLT, 5--6  1.85  (2.08)  1.93  (1.84)  2.07  (2.00)  2.67  (2.11)  F  =  0.87  >.05  --






BVRT, correct  6.90  (1.80)  5.55  (2.10)  7.15  (1.03)  6.76  (1.79)  F  =  6.14  <.05  FTP/HIV
+>MMP/HIV+;
MMP/HIV+<FTP/HIV−;
BVRT, errors  4.83  (3.17)  7.81  (4.29)  4.11  (1.85)  4.71  (3.12)  F  =  9.15  <.05  FTP/HIV+<MMP/HIV+;
MMP/HIV+<FTP/HIV−;
MMP/HIV+<MMP/HIV−
ROCF: copy  30.89  (3.26)  30.28  (4.24)  32.79  (2.43)  31.59  (3.33)  F  =  3.08  <.05  MMP/HIV+<FTP/HIV−;
ROCF: delay  15.51  (6.30)  14.45  (5.03)  18.81  (6.68)  17.38  (5.63)  F  =  3.42  <.05  MMP/HIV+<FTP/HIV−;
Visual-motor integration







Table  2  (Continued)
Neuropsychological
test





















n  =  21
WAIS:  object
assembly
30.60  (7.38)  26.55  (9.24)  33.74  (6.18)  32.10  (6.83)  F  =  5.49  <.05  MMP/HIV+<FTP/HIV−;
MMP/HIV+<PMM/HIV−;
Motor coordination




12.90 (2.42)  12.14  (2.04)  14.22  (1.69)  13.14  (1.56)  F  =  5.65  <.05  MMP/HIV+<FTP/HIV−
Finger: dominant  43.62  (11.63)  39.85  (9.58)  49.05  (5.03)  46.00  (5.99)  F  =  5.83  <.05  MMP/HIV+<FTP/HIV−;
Finger:
nondominant








WAIS: direct  digit
span
6.15  (1.05)  5.62  (1.27)  6.44  (1.15)  6.48  (1.03)  F  =  4.10  <.05  MMP/HIV+<FTP/HIV−;
MMP/HIV+<MMP/HIV−
WAIS: indirect  digit
span
4.35  (1.08)  3.93  (0.95)  4.41  (1.05)  4.24  (1.26)  F  =  1.58  >.05  --


























Table  2  (Continued)
Neuropsychological
test





















n  =  21




Stroop 2 66.25  (12.97) 58.64  (17.77) 70.56  (11.75) 68.38  (11.24) F  =  4.71 <.05 MMP/HIV+<FTP/HIV−;
MMP/HIV+<MMP/HIV−





0.23 (7.62) −2.85 (7.41) 0.34  (7.74) −1.13 (5.84) F  =  1.64 >.05 --
WCST -- number  of
categories
4.29  (1.80) 3.00  (2.13) 5.33  (1.07) 4.81  (1.81) F  =  10.65  <.05  FTP/HIV+>FTP/HIV−;
MMP/HIV+<FTP/HIV−;
MMP/HIV+<MMP/HIV−
WCST --  learning  to
learn









15.14 (9.39) 19.59  (12.52)  14.30  (7.26)  15.65  (13.77)  F  =  1.80  >.05  --
WCST-failure to
maintain  set
0.83  (1.10) 1.07  (1.39) 0.63  (0.79)  1.19  (1.54)  F  =  1.15  >.05  --
WCST-% conceptual
level  responses






21.66 (14.67) 26.76  (19.26) 15.13  (8.86) 13.13  (6.94)  F  =  5.71  <.05  MMP/HIV+>FTP/HIV−;
MMP/HIV+>MMP/HIV−
Cognitive reserve
WAIS:  vocabulary  43.92  (11.61)  41.33  (13.20)  48.67  (7.62)  51.05  (10.85)  F  =  4.50  <.05  MMP/HIV+<MMP/HIV−




















































































































mFigure  1  Neuropsychological  Z  scores  for  group
nd  months  of  abstinence.  Table  1  gives  the  mean  scores
nd  standard  deviation  in  each  group  for  these  variables,
nd  the  signiﬁcant  differences  observed  are  indicated.  More-
ver,  Chi-square  analyses  revealed  signiﬁcant  differences
etween  occupational  attainments.
nﬂuence  of  the  situation  with  respect  to  drug  use
n  order  to  determine  the  inﬂuence  of  the  situation  with
espect  to  drug  use  in  the  neuropsychological  perfor-
ance  of  seropositive  and  seronegative  drug  users,  the  drug
sers  were  divided  into  two  groups  according  to  whether
hey  were  abstaining  from  drug  use  (Drug-free  treatment
rogramme  [FTP])  or  were  included  in  a  Methadone  Mainte-
ance  Programme  (MMP).
According  to  these  results,  we  found  differences  between
he  groups  in  tests  that  assess  attention,  language,  memory,
isual-engine  integration.  Motor  coordination  and  executive
unctions.  In  resume,  the  FTP/HIV-group  performances  the
est  and  MMP/HIV+  group  obtained  the  worst  scores.  Table  2
hows  the  mean  scores  and  standard  deviations  obtained
or  the  four  groups  in  each  measurement,  and  gives  the
igniﬁcant  differences  noted  in  the  ‘‘post  hoc’’  multiple
omparison  tests.  Figure  1  represents  performance  in  the
ifferent  neuropsychological  tasks  for  each  of  the  groups,
fter  the  direct  scores  were  transformed  to  Z  scores  and
heir  direction  corrected.
iscussion
n  this  study  we  have  attempted  to  be  specially  careful
ith  some  methodological  aspects,  hence  we  followed  the
ecommendations  made  in  the  literature  in  this  respect
Bornstein,  1994;  Egan,  Deary,  &  Brettle,  1992;  Newman,
unn,  &  Harrison,  1995;  Stern,  1994;  White,  Heaton,  Monsch, The  HNRC  Group,  1995).  Along  these  lines,  we  used  a  sin-
le  risk  group,  that  of  intravenous  drug  users,  taking  into
ccount  that  it  has  been  pointed  out  that  their  neuropsy-




Vuence  of  the  situation  with  respect  to  drug  use.
isk  groups  (Egan,  Brettle,  &  Goodwin,  1992);  the  control
roups  have  the  same  socio-demographic  characteristics  as
he  seropositive  one  (Bornstein,  1994);  the  size  of  the  sam-
le  is  greater  than  one  hundred  subjects,  as  recommended
Newman  et  al.,  1995);  and,  ﬁnally,  the  criteria  for  inclusion
nd  exclusion  were  carefully  selected,  without  disregard-
ng  the  importance  of  the  representativeness  of  the  sample
Bornstein,  1994).
In  this  research  our  aim  was  to  study  the  group  of  intra-
enous  drug  users,  ﬁrst,  because  they  represent  the  greatest
ercentage  of  HIV  seropositive  subjects  and  AIDS  patients
n  Spain.  Secondly,  since  most  research  studies  use  samples
f  homosexual  and  bisexual  subjects,  their  results  are  not
pplicable  to  the  risk  group  of  intravenous  drug  users.  With
espect  to  sociodemographic  characteristics  and  drug  con-
umption  history,  the  sample  used  in  this  research  can  be
aid  to  be  representative  of  the  population  of  intravenous
rug  users  in  Spain  (Tables  1 and  2).
In  order  to  be  able  to  evaluate  the  neuropsychological
onsequences  of  HIV  infection,  it  is  important  to  deter-
ine  the  inﬂuence  of  other  variables,  whether  related  to
he  infection  or  not,  which  are  also  associated  with  the
evelopment  of  neuropsychological  disturbances  and  which
ay  make  the  seropositive  subject  more  vulnerable  neu-
opsychologically  (Cohen  et  al.,  2015;  Rodríguez-Álvarez  &
ázquez-Justo,  2002;  Vázquez-Justo  &  Rodríguez-Álvarez,
002;).  One  of  the  ﬁrst  studies  in  this  line  was  that  of
ilkins  et  al.  (1990),  who  observed  a  signiﬁcant  relation
etween  the  degree  of  neuropsychological  deterioration  and
he  presence  of  contaminating  factors.  In  our  research  we
tudied  the  inﬂuence  of  the  current  situation  with  respect
o  drug  consumption  on  the  neuropsychological  performance
f  seropositive  drug  users,  in  order  to  help  to  clarify  the
nﬂuence  of  that  factor  on  their  neuropsychological  perfor-
ance.
With  respect  to  the  inﬂuence  of  drug  use,  several  stud-es  have  disclosed  that  the  use  of  drugs,  past  or  present,
an  facilitate  the  appearance  of  neuropsychological  distur-
ances  (Albein-Urios,  Marinez-González,  Lozano,  Clark,  &






















































mNeuropsychological  functioning  in  methadone  maintenance  
London,  Robbins,  &  Sahakian,  2006;  Fernandez-Serrano,
Perez-Garcia,  Schmidt  Rio-Valle,  &  Verdejo-Garcia,  2010;
López,  Ravindran,  Mrudula,  &  Priya,  2014;  Lundqvist,  2005;
Verdejo-García  et  al.,  2012).  Although  there  is  no  evi-
dence  that  the  use  of  opiates  may  be  the  direct  cause
of  these  disturbances,  the  poly-toxicomania  pattern  these
subjects  usually  present,  the  high  frequency  of  cranial  trau-
matism  and  the  nutritional  deﬁciencies  associated  with
their  lifestyle  makes  them  a  risk  group  for  neuropsychol-
ogical  impairment  (Devlin  et  al.,  2012;  Ersche  et  al.,  2006;
Lundqvist,  2005;  Rodríguez-Álvarez  &  Vázquez-Justo,  2002).
Bearing  in  mind  that  drug  users  who  maintain  current
drug  consumption  showed  poorer  performance  in  neuropsy-
chological  tasks  than  those  in  abstinence  (Grassi  et  al.,  1995;
Verdejo-García  et  al.,  2012),  chronic  heroin-dependent  sub-
jects  had  widespread  disruption  of  white  matter  structural
connectivity  located  mainly  in  anterior  and  superior  regions
of  the  brain  (Lin  et  al.,  2013)  and  heroin  users  on  MMP
have  low  grey  matter  volume  (GMV)  in  brain  regions  that
are  hypothesized  to  inﬂuence  cognition  and  emotion,  and
the  GMV  ﬁndings  might  be  involved  comorbid  disorders  in
the  MMP  group  (Lin  et  al.,  2012),  we  posit  the  interest  of
taking  into  account  this  situation  when  evaluating  the  neuro-
psychological  performance  of  seropositive  drug  users.  Along
this  line  the  MMP  offer  a  suitable  setting  for  evaluating  the
neuropsychological  consequences  associated  with  the  active
consumption  of  opiates.
In this  research  we  sought  to  study  the  effect  of  the  situa-
tion  regarding  drug  consumption  in  seropositive  drug  users.
These  results  reveal  that  the  use  of  methadone  is  related
to  problems  of  attention,  language,  visual  memory,  motor
speed,  visual-motor  integration  and  executives  functions,
along  the  lines  of  the  results  obtained  in  the  works  cited
(Rodríguez,  2000;  Vázquez-Justo  et  al.,  2014).  It  has  also
been  demonstrated,  that  the  duration  of  MMP  was  associ-
ated  with  declining  diffusion  tensor  image  (DTI)  indices  in
the  superior  longitudinal  fasciculus  and  para-hippocampus
(Lin  et  al.,  2012).
Nevertheless,  when  we  studied  the  inﬂuence  of  this  vari-
able  on  seronegative  drug  users  we  did  not  observe  any
differences  between  subjects  in  MMP  and  in  period  of  absti-
nence  in  any  of  the  tasks  applied.  These  ﬁndings  reveal
that  continuing  in  MMP  makes  the  seropositive  subjects
more  vulnerable  neuropsychologically,  but  do  not  allow  us  to
consider  the  use  of  methadone  in  itself  as  a  risk  factor  for
neuropsychological  disturbances,  inasmuch  as  we  have  not
observed  its  inﬂuence  in  the  group  of  seronegative  drug
users.  Therefore  we  can  consider  it  to  be  a  risk  factor  for
neuropsychological  disturbances  only  in  seropositive  sub-
jects.
Not  only  can  the  inﬂuence  of  the  current  situation  as
regards  drug  consumption  on  the  neuropsychological  per-
formance  of  seropositive  subjects  be  estimated  by  the
differences  observed  in  the  two  groups  of  drug  users,  but
also  important  information  can  be  provided  by  the  com-
parison  of  the  groups,  taking  into  consideration  not  only
seropositivity  but  also  their  situation  regarding  drug  con-
sumption.  In  this  respect  we  noted  that  seropositive  subjects
in  MMP  showed  a  poorer  performance  than  seronegative
subjects  in  MMP  and  in  period  of  abstinence,  whereas  the
performance  of  seropositive  subjects  in  abstinence  is  similar
to  that  of  seronegative  subjects  in  MMP  and  in  abstinence.
t
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The  interpretation  of  these  results  leads  us  to  think  that
taying  in  MMP  can  be  considered  a  risk  factor  for  neuro-
sychological  disturbances  in  seropositive  subjects  owing
o  the  fact  that  seropositive  subjects  in  MMP  are  those
hat  show  the  poorest  performance.  These  ﬁndings  are  in
greement  with  those  studies  that  show  a  negative  effect
f  current  drug  consumption  on  cognitive  function  (Egan,
eary,  &  Brettle,  1996;  Grassi  et  al.,  1995;  Rodríguez,  2000;
ázquez-Justo  et  al.,  2000).
While  we  identiﬁed  methadone  use  as  a  risk  factor  in
eropositive  subjects,  our  results  also  reveal  that  giving  up
rugs  seems  to  have  a protective  effect  against  the  pres-
nce  of  neuropsychological  disturbances  associated  with
IV.  Once  again  we  only  identiﬁed  its  protective  effect  in
eropositive  subjects.  This  leads  us  to  think  that  the  situ-
tion  with  respect  to  drug  consumption  cannot  in  itself  be
onsidered  a  factor  of  risk  or  protection  in  the  face  of  neu-
opsychological  disturbances,  inasmuch  as  its  effect  is  only
bserved  in  seropositive  subjects.  We  think  that  its  inﬂu-
nce  may  be  due  to  a  cumulative  effect  or  to  the  effect  of
nteraction  with  seropositivity.  In  any  case,  our  data  do  not
llow  us  to  establish  a  causal  relationship  between  the  use
f  methadone  and  a  poor  neuropsychological  performance,
wing  to  the  fact  that,  besides  the  direct  effects  of  the  sub-
tance  on  the  organism,  there  could  be  other  indirect  effects
elated  to  lifestyle  and/or  the  polyconsumption  pattern  so
haracteristic  of  the  subjects  in  MMP.
This  article  shows  some  limitations,  while  assessment
ools  are  widely  used  in  other  similar  studies  may  have  been
dvisable  to  include  tests  that  deepen  in  very  subtle  aspects
f  cognitive  change  in  the  evolution  of  individuals  in  this
ype  of  methadone  programmes,  such  as  tests  to  discrimi-
ate  processing  speed,  decision  making,  problem  solving  and
eaction  times.  However  it  is  appropriate  to  use  batteries  for
ttention  and  inhibitory  control  function  that  it  was  used  in
he  sample.  In  addition,  the  sample  size  is  not  so  broad  as  to
llow  conclusive  ﬁndings  but  is  interesting  to  continue  this
ine  of  research.
Furthermore,  the  mechanisms  by  which  the  use  of
ethadone  makes  a  seropositive  subject  more  vulnera-
le  neuropsychologically  remain  to  be  determined.  We
osit,  as  a  hypothesis  to  be  conﬁrmed  in  future  stud-
es,  that  the  underlying  mechanism  may  be  related  to  the
mmune  system,  in  which  these  two  factors,  seropositivity
nd  methadone  consumption,  could  be  acting  together  and
ltering  cognitive  functioning  in  a  way  as  yet  unexplained.
To  sum  up,  our  results  lead  us  to  point  out  that  there
re  certain  factors  that  make  the  seropositive  subject  neu-
opsychologically  vulnerable,  regardless  of  seropositivity.
e  have  identiﬁed  some  risk  factors  for  seropositive  drug
sers  whose  effects  are  not  seen  in  seronegative  drug  users,
uch  as  the  use  of  methadone.  On  the  other  hand,  we  iden-
iﬁed  two  factors  that  protect  against  neuropsychological
anifestations  such  as  giving  up  drugs.  The  identiﬁcation  of
hese  factors  allows  us  to  propose  that  seropositivity  is  not
ufﬁcient  to  explain  the  neuropsychological  disturbances  of
eropositive  drug  users,  suggesting  that  these  may  be  of  a
ultifactorial  nature.
Hence,  we  feel  that  this  research  helps  to  clarify
he  lack  of  agreement  in  the  literature  on  the  presence
f  neuropsychological  disturbances  in  seropositive  sub-










































europsychological  effect  of  multiple  factors  which,  ﬁnally,
re  those  that  will  determine  the  presence  of  these  cognitive
eﬁcits  inasmuch  as  they  coexist  with  HIV  itself.  This  lack  of
ontrol  over  them  in  the  research  designs  could  explain,  at
east  partly,  the  disparity  of  results  in  the  abundant  litera-
ure  to  this  respect.  Moreover,  this  study  helps  to  outline
he  characteristics  of  the  more  neuropsychologically  vul-
erable  seropositive  subjects.  The  purpose  of  determining
 proﬁle  of  neuropsychological  vulnerability  in  seroposi-
ive  subjects  is  early  detection  with  a  view  to  preventing
he  manifestation  of  neuropsychological  disturbances,  and
ffer  swift,  suitable  treatment.  Furthermore,  it  can  be
sed  for  planning  intervention  strategies  not  only  in  health
r  work  behaviour  but  also  in  speciﬁc  aspects  related  to
nfection.
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